张青，教授，博导。现任徐州医科大学研究生院院长、细胞治疗药物产业学院院长、学科建设办公室主任、学术委员会办公室主任等职务。

入选江苏省双创团队、333人才工程、六大人才高峰计划、青蓝工程中青年学术带头人称号。博士毕业于四川大学，美国北卡罗莱纳大学教堂山分校访问学者。主要从事肿瘤微环境和免疫治疗研究，国内最早开展CAR-T治疗肿瘤的研究者之一。主持国家自然科学基金、江苏省重点研发计划等省部级及以上课题15项。以第一/通讯作者在Immunity (IF 26.3)、Cell Research(IF 25.617)、Cell Death Differ (IF 15.4)、Advanced Science(IF14.1)、Cancer Immunol Res(IF 10.1)等杂志发表SCI论文30余篇，获批国家发明专利3项，研究成果以主要完成人获中华医学科技二等奖、江苏医学科技一等奖、辽宁省科技进步二等奖。

研究方向：肿瘤微环境与免疫治疗

1.CAR-T与肿瘤微环境交互作用机制研究

2.CAR-T新型共刺激分子筛选及治疗实体瘤研究

3.肿瘤原位制备CAR-T技术开发及治疗实体瘤研究

近五年代表论文：

1.Mengmeng Lu, Runpeng Han, Hao Yang, Lin Yang, Qiuchen Zhao, Jun Wang, Zhenyang Yu, Na Liu, Yangyang Xu, Fei Luo, Yitong Mu, Hao Wang, Fang Luo, Zhenyu Wang, Minjie Zhou, Kuozeng Lin, Hang Chen, Honglei Chen, Wei Zhou, Xiong Chen, Hanjie Li, Renjin Chen,Qing Zhang*, Li Wang*, Liang Cheng*. Homeostatic maturation programs drive human cDC2s into a tolerogenic state.Immunity.2026,online.IF 26.3

2.Shishuo Sun#, Qihong Li#, Bixi Wang#, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming-Kuen Tang,Qing Zhang*. Enhancing CAR-T cell efficacy in solid tumors by inhibiting CCL5/VEGF-mediated angiogenesis.Advanced Science, 2026, e21975.IF 14.1

3.Yucheng Liu#, Junhong Yao#, Jiaxin Deng, Minjie Zhou, Kaiyue Shen, Shishuo Sun, Xiaoge Gao,Qing Zhang*, Haiheng Xu*. Attenuated bacteria-based tumor therapy: clinical application risks, marketing approval restrictions, and coping strategies.Advanced Science, 2026, 13(16): e17730.IF 14.1

4.Shishuo Sun#, Wanxin Zhao#, Yibing Liang#, Ying Xue, Qihong Li, Yifan Yuan, Zhenyu Wang, Xiaoge Gao, Yizhou Yao, Haiheng Xu, Hailong Li, Xiaoxiao Liu, Patrick Ming-Kuen Tang, Junnian Zheng,Qing Zhang*. HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.Cell Commun Signal. 2026,24(1):90.IF 8.9

5.Shuai Yang, Jiawei Song, Zhenzhen Wang, Guang Peng, Linglin Tong, Xin Li, Kexin Yang, Yang Chen, He Zhang,Qing Zhang*, Renjin Chen*. eIF6 deficiency alleviates colorectal cancer by modulating the gut microbiota and related metabolites.Cell Death Differ. 2026,online.IF 15.4

6.Shishuo Sun, Heng Xu, Wanxin Zhao, Qihong Li, Yifan Yuan, Guopeng Zhang, Shuyu Li, Bixi Wang, Wei Zhang, Xiaoge Gao, Junnian Zheng,Qing Zhang*. PA suppresses antitumor immunity of T cells by disturbing mitochondrial activity through Akt/mTOR-mediated Ca2+ flux.Cancer Lett. 2024,581:216511.IF 9.7

7.Shishuo Sun, Chao Huang, Mengmeng Lu, Heng Xu, Yifan Yuan, Wanxin Zhao, Xiaolei Hu, Bixi Wang, Wei Zhang, Xiaoge Gao, Junnian Zheng, Lishan Su,Qing Zhang*. Herpes virus entry mediator costimulation signaling enhances CAR-T cell efficacy against solid tumors through metabolic reprogramming.Cancer Immunol Res. 2023, 11(4):515-529.IF 10.1

8.Chen Zhang, Lin Fang, Xueyan Wang, Sen Yuan, Wanjing Li, Weiping Tian, Jing Chen, Qi Zhang, Yuxin Zhang,Qing Zhang*, Junnian Zheng*. Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma.Mol Ther-Oncolytics. 2022, 24: 14-25.IF 7.2

9.Mengmeng Lu#, Xiaokang Zhang#, Bixi Wang, Shishuo Sun, Xiaoge Gao, Xiaohuan Wei, Xiaolei Hu, Chao Huang, Heng Xu, Wei Zhang, Zhen Li, Xinhui Feng, Junnian Zheng*,Qing Zhang*. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.Pharmacol Res. 2021, 174:105829.IF 10.334